A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms

Kyowa Kirin

Status and phase

Enrolling

Phase 2

Phase 1

Conditions

Hematologic Neoplasms

Treatments

Drug: KK2430

Study type

Interventional

Funder types

Industry

Identifiers

NCT07629726

2430-001

Details and patient eligibility

About

KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given to people. The purpose of this Study is to find out more information about KK2430, whether it is safe in humans, how the body processes it, and if it works for treating your condition.

Enrollment

72 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants must be at least 18 years of age at the time of signing the informed consent.
At least 1 measurable diseases based on CT scan or MRI
Renal function values
Participants who have an ECOG PS score of 0, 1 or 2.
Be willing to provide a fresh tissue taken at current relapse at screening period.
Meet laboratory values at Screening i.e., ANC, Platelets, Corrected serum calcium, AST and ALT, Total bilirubin etc
Contraceptive use by [men and women] should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Women of childbearing potential and fertile men must agree to use highly effective contraceptive methods • At least 1 measurable diseases based on CT scan or MRI
Capable of giving signed informed consent
Health Information Access: Capable of providing access to personal health information via HIPAA authorization (US only).
Legal Status: Not under any administrative or legal supervision or institutionalization due to regulatory or juridical order.

Exclusion criteria

Medical Conditions
History of prior allogenic transplant.
Presence of Grade 2 peripheral neuropathy with pain.
Impaired cardiac function or clinically significant cardiac disease at Screening
Known active CNS involvement or clinical signs of meningeal involvement.
Evidence of HIV infection.
Active chronic HBV/HCV infection,
Participants with positive anti-HBc must have a negative HBV-DNA quantification test result to be enrolled.
Receipt of any anti-tumor therapy within three weeks or at least five half-lives prior to the Screening visit, whichever is shorter.
Toxicities from prior anticancer therapies that have not resolved to Grade 1 or less except for abnormal clinical values alopecia and peripheral neuropathy (participants with Grade 1 or 2 neuropathy without pain are eligible for enrollment).
Use of systemic corticosteroids exceeding 10 mg/day of prednisone or equivalent within 14 days prior to the first dose